"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (CD28 ANTIGENS) and CD80 antigens (B7-1 ANTIGEN).
| Descriptor ID |
D019139
|
| MeSH Number(s) |
G12.900
|
| Concept/Terms |
Tumor Escape- Tumor Escape
- Tumor Immune Evasion
- Evasion, Tumor Immune
- Evasions, Tumor Immune
- Immune Evasions, Tumor
- Tumor Immune Evasions
- Immune Evasion, Tumor
- Immune Escape, Tumor
- Tumor Immune Escape
|
Below are MeSH descriptors whose meaning is more general than "Tumor Escape".
Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".
This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 3 | 5 |
| 2021 | 2 | 0 | 2 |
| 2023 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Escape" by people in Profiles.
-
A Spatiotemporal Model of CXCL10 as a Master Regulator of Immune Evasion and Metastasis in Osteosarcoma. Int J Mol Sci. 2025 Dec 27; 27(1).
-
PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination. J Clin Invest. 2023 02 01; 133(3).
-
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021 02; 9(2).
-
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021 01 04; 131(1).
-
M2-TAM subsets altered by lactic acid promote T-cell apoptosis through the PD-L1/PD-1 pathway. Oncol Rep. 2020 11; 44(5):1885-1894.
-
Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci. 2021 Apr; 64(4):534-547.
-
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. Cancer Discov. 2020 09; 10(9):1374-1387.
-
Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. J Immunother Cancer. 2020 02; 8(1).
-
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1224:117-140.
-
Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer. Trends Cancer. 2020 01; 6(1):40-48.